Ozempic · DIN 02471477 · 1.34 mg/mL · injection solution-pre-filled pen 1.5mL Pk
Limited Use, Reason for Use code 666 requiredDormant since July 24, 2026 · checked November 17, 2026 · What does dormant mean?
StatusLimited Use, Reason for Use code 666 required
Write on scriptReason for Use code 666 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 666
Reason for Use code 666
For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate.
Semaglutide is not funded in combination with another glucagon-like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor.
Injectable semaglutide is not funded in combination with oral semaglutide. Coverage is only provided for one dosage format.
Reimbursed dose: As per the product monograph
Coverage limit:
LU Authorization Period: Indefinite
Savings card: innoviCares lists Ozempic (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Ozempic · DIN 02471477
Manufacturer: Novo Nordisk Canada Inc; listing date 2019-09-30
Health Canada: Dormant since 2026-07-24 · brand OZEMPIC · ATC A10BJ06 SEMAGLUTIDE · form Solution · route Subcutaneous · ingredients SEMAGLUTIDE 1.34 MG/ML · company Novo nordisk canada inc · schedule Schedule d, Prescription
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02471477)
Source record
DIN 02471477: Ozempic
Raw flags: insOH=Y, sec12=Y, sec3=Y
Item: 682006002; group id 760; item number 1865; lccId 00383; manufacturer id NOO
Source form: Inj Sol-Pref Pen 1.5mL Pk; strength: 1.34mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; diabetes medication flag
Source prices (unrounded): $227.9400; ministry $78.1410
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02471477
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96059
Interchangeable products
Semaglutide Injection · DIN 02567806 · $78.1410
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Dormant since July 24, 2026 — choose a marketed DIN from the same-category list.